BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22261445)

  • 1. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
    Avet-Loiseau H; Soulier J; Fermand JP; Yakoub-Agha I; Attal M; Hulin C; Garderet L; Belhadj K; Dorvaux V; Minvielle S; Moreau P;
    Leukemia; 2010 Mar; 24(3):623-8. PubMed ID: 20072152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
    Chang H; Yeung J; Qi C; Xu W
    Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
    Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
    Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
    Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
    Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
    Kelley TW; Baz R; Hussein M; Karafa M; Cook JR
    Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
    Reece D; Song KW; Fu T; Roland B; Chang H; Horsman DE; Mansoor A; Chen C; Masih-Khan E; Trieu Y; Bruyere H; Stewart DA; Bahlis NJ
    Blood; 2009 Jul; 114(3):522-5. PubMed ID: 19332768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
    Dimopoulos MA; Chen C; Spencer A; Niesvizky R; Attal M; Stadtmauer EA; Petrucci MT; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
    Leukemia; 2009 Nov; 23(11):2147-52. PubMed ID: 19626046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
    Klein U; Jauch A; Hielscher T; Hillengass J; Raab MS; Seckinger A; Hose D; Ho AD; Goldschmidt H; Neben K
    Cancer; 2011 May; 117(10):2136-44. PubMed ID: 21523726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
    Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
    Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
    Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
    Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
    Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.